Elvaston, an entrepreneur-led private equity firm, has sold its participation in Magnolia International to GENUI. The investment company has acquired a majority stake in Magnolia and will injects significant growth capital into the company. Magnolia
Ufenau Capital Partners has acquired a majority stake in Dr. Niedermaier Pharma Group, a leading producer and supplier of organic nutritional supplements and natural cosmetics with headquarters in Hohenbrunn near Munich (Germany) and in Appenzell.
Nicolas Diebold will be the new Dean of the Faculty of Law at the University of Lucerne on August 1, 2022. In addition, Bernhard Rütsche takes over as Vice-Chancellor for University Development and Vice-Chancellor of the
Baker McKenzie has acted as legal advisor on the successful offering and listings of Global Depositary Receipts (GDR) on SIX Swiss Exchange of four Chinese companies: GEM Co., Gotion High-tech Co., Keda Industrial Group Co.,
BGPartner has advised in acquisition of tradition Hotel Florhof in Zurich. Silvio Denz, majority shareholder and chairman of Lalique Group, together with entrepreneur Peter Spuhler, have acquired the Hotel Florhof in Zurich, a Zurich hotel
Banking & Finance
Schellenberg Wittmer advises LokRoll3 in debt financing acquisition of locomotives
Schellenberg Wittmer has advised the Lucerne-based LokRoll3, a locomotives holding company managed by Reichmuth & Co Investment Management, in a debt financing transaction for the acquisition of 35 newly-built Vectron AC locomotives from Siemens Mobility. The
Schellenberg Wittmer has advised Aldo Group International in the successful completion of its Swiss composition proceedings and the exit financing. Aldo Group International is part of the ALDO Group, a Canadian multinational shoe and accessories
Homburger has advised Basler Kantonalbank in connection with the issuance of CHF 110 m Social Bonds by the Canton Basel Stadt. The Basler Kantonalbank has acted as lead manager and the Bonds will be listed on
Mosanna Therapeutics, a Basel-based biotechnology company, has closed a Seed Financing Round led by Forty51 Ventures. The proceeds will be used for formulation and manufacturing optimization of the molecule MOS118 and for regulatory activities in
Novaremed, a privately held clinical-stage biopharmaceutical company and NeuroFront Therapeutics, a China-based clinical stage neuroscience biotech company, jointly announced the signing of an exclusive collaboration and commercialization agreement for non-opioid investigational drug, NRD.E1. The
